AYA.ASX: June Quarterly Activities Report and Appendix 4C

June Quarterly Activities Report and Appendix 4C

Stock	ARTRYA Ltd (AYA.ASX)
Release Time	29 Jul 2026, 8:37 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Artrya Ltd June Quarterly Activities Report

Key Points

U.S. customers progress with Salix® platform
Northeast Georgia Health System goes live in July
Salix® Coronary Flow validation nears completion
SAPPHIRE Study commences with investigator meeting
Clinical Advisory Board formation advanced

Full Summary

Artrya Limited, a medical technology company, released its June Quarterly Activities Report highlighting significant progress in commercializing its Salix® AI-powered platform for coronary artery disease assessment. U.S. customers, including Tanner Health and Northeast Georgia Health System, have progressed with platform deployment. Salix® Coronary Flow validation is nearing completion, with FDA submission imminent. The SAPPHIRE Study has commenced, and the Clinical Advisory Board formation has advanced, strengthening Artrya's U.S. clinical strategy. Financial results show a pro forma cash position of $74.0M at 30 June 2026.

Outlook

Artrya is well positioned to accelerate the commercialisation of Salix® with a strong balance sheet, expanding commercial pipeline, and increasingly repeatable deployment model.